# Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-first-quarter-2026-financial-results
Ticker: CRVS
Company: Corvus Pharmaceuticals
Source: Corvus Pharmaceuticals
Published: 2026-05-07 20:01 EST
Original Source URL: https://investor.corvuspharma.com
## Summary

Soquelitinib clinical development for atopic dermatitis advancing with Phase 1 cohort 4 positive data and initiation of Phase 2 trial during the quarter New immunologic and biomarker data supporting the potential for drug-free remissions with soquelitinib to be presented at Society for

## Article Body
Soquelitinib clinical development for atopic dermatitis advancing with Phase 1 cohort 4 positive data and initiation of Phase 2 trial during the quarter New immunologic and biomarker data supporting the potential for drug-free remissions with soquelitinib to be presented at Society for
## Recent Company News
- 2026-05-20 20:01 EST — [Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-conference-and-goldman-sachs-47th-annual-global-healthcare-conference) — Source: Corvus Pharmaceuticals
- 2026-05-14 11:00 EST — [Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-presents-soquelitinib-phase-1-atopic-dermatitis-data-at-the-society-for-investigative-dermatology-sid-annual-meeting) — Source: Corvus Pharmaceuticals
- 2026-05-07 20:01 EST — [Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-first-quarter-2026-financial-results) — Source: Corvus Pharmaceuticals
- 2026-04-23 11:30 EST — [Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors) — Source: Corvus Pharmaceuticals
- 2026-04-21 11:30 EST — [Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-to-host-investor-and-analyst-meeting-on-may-14-2026-to-highlight-soquelitinib-data-being-presented-at-the-society-for-investigative-dermatology-sid-annual-meeting) — Source: Corvus Pharmaceuticals
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)